Diffuse large B-cell lymphomas with plasmablastic differentiation

Teruya‐Feldstein, Julie

doi:10.1007/s11912-005-0062-5

Cited by 43 publications

(29 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several morphologic variants of DLBCL including centroblastic, immunoblastic, anaplastic, T-cell/histiocyte rich, and PBL [31]. The spectrum of DLBCL with plasmablastic features has widened to include subtypes, such as PBL of oral mucosa type, PBL with plasmacytic differentiation, classic PEL, extracavitary/solid PEL or HHV8-associated DLBCL, and ALK-positive DLBCL [32,33]. PBL is a distinct subtype of DLBCL, that is, characterized by an immunoblastic and/ or plasmablastic morphology, Ig heavy chain gene rearrangement, and consistent expression of plasma cell antigens (see Fig.…”

Section: Discussionmentioning

confidence: 99%

HIV‐associated plasmablastic lymphoma: Lessons learned from 112 published cases

2008

View full text Add to dashboard Cite

Plasmablastic lymphoma (PBL) is a distinct subtype of non-Hodgkin B-cell lymphoma, originally described with a strong predilection to the oral cavity of human immunodeficiency virus (HIV)-infected individuals. Data regarding patient age and gender, HIV status, initiation of and response to highly active antiretroviral therapy (HAART), tumor extent, pathology, treatment, and outcome were extracted from 112 cases of PBL identified in the literature. The median age at presentation was 38 years with a male predominance of 7:1, and the median CD41 count was 178 cells/mm 3 . PBL presented on average 5 years after diagnosis of HIV. Common primary sites of presentation included the oral cavity, gastrointestinal tract, and lymph nodes. Most cases presented with either stage I or stage IV disease. There was a variable expression of B-cell markers in tumor cells, but plasma cell markers were expressed in all cases. EBV was detected in 74%. Chemotherapy was used to treat 55% patients and was combined with radiotherapy in 21% cases. Complete response was obtained in 66% of treated cases; the majority of these responses were seen after CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). The refractory/relapsed disease rate was 54%. Death occurred in 53% of patients, with a median overall survival of 15 months. Sex, CD41 count, viral load, clinical stage, EBV status, primary site of involvement, and use of CHOP failed to show an association with survival. PBL is an aggressive B-cell lymphoma that presents in both oral and extra-oral sites of chronically HIV-infected immunosuppressed young men. Am. J. Hematol. 83:804-809, 2008. V

show abstract

Section: Discussionmentioning

confidence: 99%

HIV‐associated plasmablastic lymphoma: Lessons learned from 112 published cases

2008

View full text Add to dashboard Cite

show abstract

“…In contrast, PBL associated with multicentric Castleman disease, DLBCL with secretory differentiation, pyothorax-associated lymphoma, and atypical Burkitt lymphoma with plasmacytoid differentiation have morphologic appearances of plasma cell differentiation, but maintain a mature B-cell (CD20 positive) phenotype. These tumors as well as extramedullary plasmablastic tumors secondary to multiple myeloma or plasmacytomas are included in the differential diagnosis [21].…”

Section: Discussionmentioning

confidence: 99%

Prolonged survival of an HIV‐infected patient with plasmablastic lymphoma of the oral cavity

et al. 2006

View full text Add to dashboard Cite

Plasmablastic lymphoma is an aggressive subtype of diffuse large B‐cell lymphoma that is mainly observed in patients with the human immunodeficiency virus (HIV) infection, and it tends to arise in the oral cavity. We present a case of an HIV‐infected patient with plasmablastic lymphoma with prolonged survival. The 30‐yr‐old woman was found to have an oral lesion at the time of the diagnosis of HIV infection. Histological and immunochemical examination of biopsy of the oral lesion showed plasmablastic lymphoma (CD138+). She received two cycles of cyclophosphamide, vincristine, doxorubicin, and prednisolone (CHOP) that started 10 weeks after the initiation of antiretroviral therapy. The continuing pancytopenia and an adenoviral febrile infection did not permit further antineoplastic treatment. A gradual decrease of the oral lesion was noted after the second cycle of chemotherapy that led to the disappearance of the lesion 7 months later. The patient remains in complete remission 61 months after the diagnosis of plasmablastic lymphoma. Am. J. Hematol., 2007. © 2006 Wiley‐Liss, Inc.

show abstract

“…Recent reviews on B-cell lymphomas with plasmablastic differentiation and acquired immunodeficiency syndrome-related lymphomas have been written and can be recommended. [61][62][63] DLBCL arising in special anatomic sites…”

Section: Dlbcl With Plasmablastic Morphologymentioning

confidence: 99%

Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities

2006

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) as defined by the World Health Organization (WHO) classification is clinically, morphologically and genetically a heterogeneous group of malignant proliferations of large lymphoid B cells. Over the last 6 years, several studies have been published improving our understanding of these lymphomas. These studies analyzed DLBCL by their gene expression profile, provided further information on some of the variants of DLBCL listed in the WHO classification and stressed the impact of the site of origin of these tumors. This review summarizes these recent data and explores their impact on the recognition of new clinicopathological lymphoma entities.

show abstract

Diffuse large B-cell lymphomas with plasmablastic differentiation

Cited by 43 publications

References 48 publications

HIV‐associated plasmablastic lymphoma: Lessons learned from 112 published cases

HIV‐associated plasmablastic lymphoma: Lessons learned from 112 published cases

Prolonged survival of an HIV‐infected patient with plasmablastic lymphoma of the oral cavity

Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities

Contact Info

Product

Resources

About